chufangao/CTO huggingface dataset:
Clinical trial NCT06630572: Rifaximin in Cirrhosis: Effects on Endotoxin and Haemostatic Indexes
Official title: Rifaximin Blunted Higher Levels of Endotoxin in Cirrhosis Patients: a Randomized, Double Blind, Short Term Interventional Trial
Sponsor: University of Roma La Sapienza (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Because drug is expired
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-03
Primary completion date: 2022-04-03
Completion date: 2024-08-01
Plan to share individual participant data: NO
Clinical trial NCT03835728: Efficacy of Ocrelizumab in Autoimmune Encephalitis
Official title: Exploratory Study of Efficacy of Ocrelizumab in Autoimmune Encephalitis
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Failed to meet target enrollment and study was discontinued
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-22
Primary completion date: 2020-10-02
Completion date: 2020-10-02
Limitations and caveats: Early termination of trial due to inadequate recruitment. Small numbers of subjects prevents definitive analysis of results
Plan to share individual participant data: YES
Clinical trial NCT03467152: Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies
Official title: A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies
Sponsor: Eisai Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 326.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-04
Primary completion date: 2020-04-15
Completion date: 2020-04-15
Baseline population: The safety analysis set included the group of participants who received at least 1 dose of study drug and had at least 1 post randomization safety assessment.
Clinical trial NCT04422275: Coronavirus Smell Therapy for Anosmia Recovery
Official title: Coronavirus Smell Therapy for Anosmia Recovery
Acronym: Co-STAR
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Funding not received
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-06-01
Primary completion date: 2023-06-01
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT03593473: Inhaled Oxytocin and HPA Axis Reactivity
Official title: The Psychobiology of Resilience in Mother-child Pairs: Inhaled Oxytocin and HPA Axis Reactivity
Sponsor: University of North Carolina, Chapel Hill (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 109.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-07
Primary completion date: 2023-07-25
Completion date: 2023-07-25
Plan to share individual participant data: YES
IPD sharing description: Data will be shared according to the most recent NIH guidelines.
IPD time frame: Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB) and executes a data use/sharing agreement with the University of North Carolina (UNC).
IPD access criteria: Individual level data sharing will be subject to local IRB approval, individual written informed consents, and national law
Clinical trial NCT05271279: A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors
Official title: A Single-Arm, Open-Label, Investigator-Initiated Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Oncolytic Virus Injection (OVV-01) in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors
Sponsor: Beijing Boren Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Research and development strategy adjustment
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-12-24
Primary completion date: 2022-08-29
Completion date: 2022-08-29
Plan to share individual participant data: NO
Clinical trial NCT04566445: HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
Official title: HORIZON: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Sponsor: Gyroscope Therapeutics Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated due to the interim analysis demonstrating lack of treatment efficacy.
Enrollment: 255.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-09-28
Primary completion date: 2024-06-10
Completion date: 2024-06-10
Clinical trial NCT03584373: Pain Outcomes of Non-opioid vs. Opioid Analgesia for Kidney Stone Surgery.
Official title: Pain Outcomes of Non-opioid Analgesia After Ureteroscopy or Percutaneous Nephrolithotomy for Nephrolithiasis: a Prospective Randomized Controlled Trial.
Acronym: PO-NOA
Sponsor: Montefiore Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 119.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-27
Primary completion date: 2022-03-23
Completion date: 2022-03-23
Clinical trial NCT02692651: A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
Official title: A Comparison of Fidaxomicin and Oral Vancomycin for the Treatment of Clostridium Difficile Infection (CDI) in Hospitalized Patients Receiving Concomitant Antibiotics for the Treatment of Concurrent Systemic Infections
Sponsor: University of Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 144.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-05-01
Primary completion date: 2021-05-23
Completion date: 2021-06-23
Plan to share individual participant data: NO
Clinical trial NCT04726098: Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19
Official title: Efficacy of Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19
Acronym: HIGHLOWDEXA
Sponsor: Hospital Clinico Universitario de Santiago (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 198.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-15
Primary completion date: 2021-08-31
Completion date: 2021-08-31
Plan to share individual participant data: NO
Clinical trial NCT02642939: Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Official title: A Phase II Study of Treatment With Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Two or More Previous Chemotherapy Regimens
Sponsor: Check, Jerome H., M.D., Ph.D. (INDIV)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of enrollment
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-12-31
Primary completion date: 2020-10-15
Completion date: 2020-10-15
Plan to share individual participant data: YES
IPD sharing description: See below
IPD time frame: 1 year after completion of study
Clinical trial NCT03777176: A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
Official title: A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism
Sponsor: Zealand Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 32.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-07
Primary completion date: 2020-08-31
Completion date: 2020-10-05
Plan to share individual participant data: NO
Clinical trial NCT04998201: Study of ARO-APOC3 in Adults With Mixed Dyslipidemia
Official title: A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Mixed Dyslipidemia
Acronym: MUIR
Sponsor: Arrowhead Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 353.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-09-28
Primary completion date: 2023-02-10
Completion date: 2023-08-14
Plan to share individual participant data: NO
Clinical trial NCT02359175: Supplementary Epidural Analgesia in Video-Assisted Thoracic Surgery (VATS) - The SEAVATS Study
Official title: Supplementary Epidural Analgesia in Video-Assisted Thoracic Surgery (VATS) - The SEAVATS Study
Acronym: SEAVATS
Sponsor: Odense University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 161.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-02-28
Primary completion date: 2019-01-24
Completion date: 2023-03-22
Plan to share individual participant data: NO
Clinical trial NCT02151604: Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy
Official title: A Study to Determine Regional Lung Function in Patients With Non-small Cell Lung Cancer (NSCLC) Undergoing Radiotherapy Using Hyperpolarized Xenon Gas MR Imaging
Sponsor: Oxford University Hospitals NHS Trust (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 22.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-04-23
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Baseline population: Not all participants have had their baseline measurements taken due to a number of interim ethics approved study amendments and some logistic issues. But age, sex, CT and HPXMRI were acquired for all patients enrolled in the study.
Limitations and caveats: 3 patients were recruited prior a substantial amendment was put in place thus were excluded from the analysis due to different study objectives being in place at that time.~4 patients were not able to breath hold during the MRI scan and therefore good quality image scans of their lungs could not be obtained on those occasions. The scans were excluded from the analysis.
Clinical trial NCT04792970: Randomized Controlled Trial of Talc Instillation In Addition To Daily Drainage Through a Tunneled Pleural Catheter to Improve Rates of Outpatient Pleurodesis in Patients With Malignant Pleural Effusion
Official title: Randomized Controlled Trial of Talc Instillation In Addition To Daily Drainage Through a Tunneled Pleural Catheter to Improve Rates of Outpatient Pleurodesis in Patients With Malignant Pleural Effusion - The ASAP II Trial
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study enrollment not met
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-18
Primary completion date: 2022-10-07
Completion date: 2022-10-07
Plan to share individual participant data: NO
Clinical trial NCT02927314: A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
Sponsor: Can-Fite BioPharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-11-27
Primary completion date: 2020-03-01
Completion date: 2020-03-01
Clinical trial NCT03872011: Vitamin C, Thiamine and Hydrocortisone for the Treatment of Septic Shock
Official title: Initiation of Vitamin C, Thiamine and Hydrocortisone Therapy for Septic Shock in Adults: A Randomized Clinical Trial
Sponsor: Northern Jiangsu People's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 408.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-19
Primary completion date: 2021-09-20
Completion date: 2021-09-20
Plan to share individual participant data: NO
Clinical trial NCT03390101: An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis
Official title: An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis
Acronym: BCD-085-7
Sponsor: Biocad (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 213.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-12-26
Primary completion date: 2018-07-30
Completion date: 2022-01-20
Baseline population: All randomized subjects
Plan to share individual participant data: NO
Clinical trial NCT03822351: Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
Official title: A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)
Acronym: COAST
Sponsor: MedImmune LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 189.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-12-19
Primary completion date: 2023-07-18
Completion date: 2023-07-18
Baseline population: The Intent-to-treat (ITT) population included participants who were randomized and were analyzed according to their randomized treatment group
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT06489860: SARS-CoV-2 Safety Study for the Treatment of COVID-19
Official title: SARS-CoV-2 Safety Study for the Treatment of COVID-19
Acronym: SARS-CoV-2
Sponsor: DHA Coffee Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: My record is not overseen by an IRB, I change the Overall Status to Withdrawn.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2024-10-01
Primary completion date: 2024-10-02
Completion date: 2024-10-04
Plan to share individual participant data: NO
IPD sharing description: 20 -1 g Packets Net Weight 0.70 oz (20 g) Directions: For adults and for Children 1-12 years old. Indication: Treated the SARS-CoV-2 COVID-19 within 20 days Ingredient: Organic Rice 95% and Honey 5% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved.~Participants: Use 4 to 5 packets, use one pack each time after two hours. Use within two years from the manufacturing date. Humidification: \<5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Storage normal conditions in dry, cool and temperature from 15 °C to 32 °C Store in a dry environment (75% humidity).
Clinical trial NCT02781584: Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
Official title: A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 220.0 (ACTUAL)
Number of arms: 13.0
Start date: 2016-06-13
Primary completion date: 2020-12-17
Completion date: 2020-12-17
Plan to share individual participant data: NO
Clinical trial NCT04335201: Defibrotide in COVID-19 Pneumonia
Official title: Use of Defibrotide to Reduce Progression of Acute Respiratory Failure Rate in Patients With COVID-19 Pneumonia
Acronym: DEFI-VID19
Sponsor: IRCCS San Raffaele (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-05-20
Primary completion date: 2021-04-07
Completion date: 2021-05-28
Clinical trial NCT05082155: Continuous Erector Spinae Plane Blocks to Treat Postoperative Pain After Open Gynecologic Procedures Via a Low Transverse (Pfannenstiel) Incision
Official title: Continuous Erector Spinae Plane Blocks to Treat Postoperative Pain After Open Gynecologic Procedures Via a Low Transverse (Pfannenstiel) Incision: A Randomized, Triple-masked, Placebo-controlled, Split-body Clinical Trial
Sponsor: University of California, San Diego (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: surgeons stopped doing procedures
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-01
Primary completion date: 2022-05-24
Completion date: 2022-05-24
Plan to share individual participant data: NO
Clinical trial NCT03760666: A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Official title: A Phase 1b/2a Open-label, Multi-center Study to Assess the Safety, Efficacy and Pharmacokinetics of Intrapatient Dose-adjusted Brequinar and Inhibition of Dihydroorotate Dehydrogenase (DHODH) in Adult Subjects With AML
Sponsor: Clear Creek Bio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: No efficacy observed, COVID-19 caused sites to shut down
Enrollment: 17.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-20
Primary completion date: 2020-12-31
Completion date: 2021-02-09
Baseline population: Data were reported and analyzed by cohort.
Limitations and caveats: CCB-01 was a small, open-label study in patients who had exhausted all other therapy options for their relapsed/refractory acute myeloid leukemia (AML). The study was stopped early due to lack of efficacy and inability to recruit new patients during the COVID-19 pandemic.
Plan to share individual participant data: YES
IPD sharing description: Clear Creek Bio is committed to responsible data sharing regarding the clinical trials we sponsor. Data that may be shared include access to anonymized participant and trial level data (analysis data sets), as well as other information (e.g., protocol) as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: Requests for data can be submitted at any time and if the below conditions are met data will be accessible for 12 months, with possible extensions considered.
IPD access criteria: Requests for data may be made by qualified researchers who plan to engage in rigorous, independent scientific research. Data will be provided following review and approval of a research proposal including a formal statistical analysis plan and execution of a Data Sharing Agreement.
Clinical trial NCT04565249: Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19
Official title: A Randomized, Double-blind, Dose-ranging, Placebo Controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 (INTEGRIS-ARDS)
Sponsor: Pliant Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study halted and will not resume; participants are no longer being examined or receiving intervention
Enrollment: 6.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-10-22
Primary completion date: 2021-06-01
Completion date: 2021-08-02
Baseline population: Study was discontinued before completion of enrollment of Dose 1.
Limitations and caveats: The study was discontinued prior to completion of enrollment of Dose 1 due to the lack of participant availability following the introduction of COVID-19 vaccines as well as the increased and successful measures to contain the virus leading to a dramatic decrease in the number of severe and critical COVID-19 patients with ARDS. As a result, the study did not reach the target number of participants needed to achieve target power and statistically reliable results.
Plan to share individual participant data: NO
Clinical trial NCT04119336: Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
Official title: A Phase II Study of Nivolumab in Combination With Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study closure initiated by industry funding sponsor for commercial reasons.
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-14
Primary completion date: 2020-11-12
Completion date: 2022-03-30
Plan to share individual participant data: YES
IPD sharing description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD time frame: Data can be shared no earlier than 1 year following the date of publication
IPD access criteria: MGH - Contact the Partners Innovations team at http://www.partners.org/innovation
Clinical trial NCT04090190: Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
Official title: Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 20.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-30
Primary completion date: 2021-05-30
Completion date: 2021-10-31
Plan to share individual participant data: NO
Clinical trial NCT03586544: Reducing Exercise-induced Bronchoconstriction in Children With Asthma and Obesity
Official title: Asthma and Childhood Obesity: Understanding Potential Mechanisms and Identifying Strategies to Improve Respiratory Symptoms
Sponsor: University of Nevada, Las Vegas (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The study was halted prematurely due to COVID 19.
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-18
Primary completion date: 2020-03-30
Completion date: 2021-03-30
Baseline population: Baseline analysis is shown for all randomized participants including the two participants who did not complete the interval warm-up first arm.
Plan to share individual participant data: NO
IPD sharing description: There is no current plan to share individual participant data.